Advertisement

Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial

      Highlights

      • Addition of evacetrapib to statin therapy produces favorable effects on atherogenic and protective lipid measures.
      • Increases in apolipoproteins C-III and E, in addition to C-reactive protein, may exert adverse cardiovascular effects.
      • These findings may provide mechanistic rationale for the lack of efficacy of evacetrapib in large outcomes trials.
      • It remains to be determined whether CETP inhibition is useful in secondary prevention.

      Abstract

      Background and aims

      The optimal approaches to management of patients treated with moderate statin doses on lipid parameters are unknown. The ACCENTUATE study aimed to compare the effects of adding the cholesteryl ester transfer protein inhibitor (CETP) evacetrapib, ezetimibe or increasing statin dose in atorvastatin-treated high-vascular risk patients on lipid parameters.

      Methods

      366 patients with atherosclerotic cardiovascular disease (ASCVD) and/or diabetes were treated with atorvastatin 40 mg/day for 28 days prior to randomization to atorvastatin 40 mg plus evacetrapib 130 mg, atorvastatin 80 mg, atorvastatin 40 mg plus ezetimibe 10 mg or atorvastatin 40 mg plus placebo, daily for 90 days at 64 centers in the United States. Lipid parameters, safety and tolerability were measured.

      Results

      Addition of evacetrapib significantly reduced LDL-C (−33%) compared with ezetimibe (−27%, p=0.045), increasing statin dose (−6%) and statin alone (0%, p<0.001). Evacetrapib also decreased apoB by 23% compared to 19% with ezetimibe (p=0.06) and 7% with increased statin dose (p<0.001), and reduced Lp(a) by 29% (p<0.001 vs. other groups). Evacetrapib increased HDL-C (+125%), apoA-I (+46%), apoC-III (+50%) and apoE (+28%) (p<0.001 vs. other groups). Non-ABCA1-mediated efflux increased by 53% (p<0.001 vs. other groups) with evacetrapib. ABCA1-mediated efflux also increased by 13% with evacetrapib (p<0.001 vs. ezetimibe, p=0.002 vs. increasing statin dose, and p=0.004 vs. statin alone). Addition of evacetrapib to atorvastatin produced an increase in hsCRP compared with ezetimibe (p=0.02).

      Conclusions

      While evacetrapib improved traditional atherogenic and putative protective lipid measures compared with ezetimibe and increasing statin dose in patients with ASCVD and/or diabetes, it also adversely affected novel atherogenic risk factors. These findings may contribute to the lack of clinical benefit observed in the ACCELERATE trial.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N. Engl. J. Med. 1998; 339: 1349-1357
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • et al.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615-1622
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • et al.
        Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N. Engl. J. Med. 1996; 335: 1001-1009
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N. Engl. J. Med. 1995; 333: 1301-1307
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • et al.
        Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • et al.
        JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N. Engl. J. Med. 2008; 359: 2195-2207
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • et al.
        Pravastatin or atorvastatin evaluation infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N. Engl. J. Med. 2004; 350: 1495-1504
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • et al.
        Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N. Engl. J. Med. 2005; 352: 1425-1435
        • Nicholls S.J.
        HDL: still a target for new therapies?.
        Curr. Opin. Investig. Drugs. 2008; 9: 950-956
        • Barter P.J.
        • Caulfield M.
        • Eriksson M.
        • et al.
        ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events.
        N. Engl. J. Med. 2007; 357: 2109-2122
        • Schwartz G.G.
        • Olsson A.G.
        • Abt M.
        • et al.
        dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
        N. Engl. J. Med. 2012; 367: 2089-2099
        • Nicholls S.J.
        • Brewer H.B.
        • Kastelein J.J.
        • et al.
        Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
        JAMA. 2011; 306: 2099-2109
        • Nicholls S.J.
        • Lincoff A.M.
        • Barter P.J.
        • et al.
        Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial.
        Am. Heart J. 2015; 170: 1061-1069
        • Cannon C.P.
        • Shah S.
        • Dansky H.M.
        • et al.
        DEFINE Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease.
        N. Engl. J. Med. 2010; 363: 2406-2415
      2. https://www.eas-society.org/news/291661/EAS-2016-Innsbruck-Highlights-from-the-congress-Monday-May-30.htm Accessed December 19, 2016.

      3. http://www.thecardiologyadvisor.com/acc-meeting-highlights/evacetrapib-did-not-reduce-cv-events-in-high-risk-patients/article/487228/ Accessed December 19, 2016.

        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • et al.
        IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes.
        N. Engl. J. Med. 2015; 372: 2387-2397